Literature DB >> 20238135

Characterisation of bacteria in ascites--reporting the potential of culture-independent, molecular analysis.

G B Rogers1, L E Russell, P G Preston, P Marsh, J E Collins, J Saunders, J Sutton, D Fine, K D Bruce, M Wright.   

Abstract

Spontaneous bacterial peritonitis (SBP) is a severe complication of liver disease. A significant proportion of patients have culture-negative ascites, despite having similar signs, symptoms and mortality to those with SBP. Therefore, empirical antibiotic treatment for infection is often started without knowledge of the causative organisms. Here, we investigated the potential of molecular techniques to provide rapid and accurate characterisation of the bacteria present in ascitic fluid. Ascites samples were obtained from 29 cirrhotic patients undergoing clinically indicated therapeutic paracentesis. Bacterial content was determined by terminal restriction fragment length polymorphism (T-RFLP) analysis, quantitative polymerase chain reaction (PCR) and 16S ribosomal clone sequence analysis. Bacterial signal was detected in all samples, compared to three out of ten using standard methods. Bacterial loads ranged from 5.5 x 10(2) to 5.4 x 10(7) cfu/ml, with a mean value of 1.9 x 10(6) cfu/ml (standard deviation +/- 9.6 x 10(6) cfu/ml). In all but one instance, bacterial species identified by culture were also confirmed by molecular analyses. Preliminary data presented here suggests that culture-independent, molecular analyses could provide rapid characterisation of the bacterial content of ascites fluid, providing a basis for the investigation of SBP development and allowing early and targeted antibiotic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238135     DOI: 10.1007/s10096-010-0891-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  31 in total

1.  Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998.

Authors:  P J Thuluvath; S Morss; R Thompson
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

2.  Development of broad-range 16S rDNA PCR for use in the routine diagnostic clinical microbiology service.

Authors:  Kathryn A Harris; John C Hartley
Journal:  J Med Microbiol       Date:  2003-08       Impact factor: 2.472

3.  The evolution of ascitic fluid analysis in the diagnosis of spontaneous bacterial peritonitis.

Authors:  Bruce A Runyon
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

Review 4.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis.

Authors:  B A Runyon
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study.

Authors:  A Rimola; J M Salmerón; G Clemente; L Rodrigo; A Obrador; M L Miranda; C Guarner; R Planas; R Solá; V Vargas
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

7.  Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls.

Authors:  Johan Dicksved; Mathilda Lindberg; Magnus Rosenquist; Helena Enroth; Janet K Jansson; Lars Engstrand
Journal:  J Med Microbiol       Date:  2009-04       Impact factor: 2.472

8.  Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease.

Authors:  R Terg; D Levi; P Lopez; C Rafaelli; S Rojter; R Abecasis; F Villamil; H Aziz; A Podesta
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

9.  Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites.

Authors:  José Such; Rubén Francés; Carlos Muñoz; Pedro Zapater; Juan A Casellas; Ana Cifuentes; Francisco Rodríguez-Valera; Sonia Pascual; Javier Sola-Vera; Fernando Carnicer; Francisco Uceda; José M Palazón; Miguel Pérez-Mateo
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

Review 10.  Studying bacterial infections through culture-independent approaches.

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  J Med Microbiol       Date:  2009-06-25       Impact factor: 2.472

View more
  11 in total

1.  Performance of the LightCycler SeptiFast test Mgrade in detecting microbial pathogens in purulent fluids.

Authors:  Silvia Sancho-Tello; Dayana Bravo; Rafael Borrás; Elisa Costa; Beatriz Muñoz-Cobo; David Navarro
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

2.  Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports.

Authors:  M Boaretti; F Castellani; M Merli; C Lucidi; M M Lleo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-11       Impact factor: 3.267

3.  Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites.

Authors:  Sandra Krohn; Stephan Böhm; Cornelius Engelmann; Jan Hartmann; Annika Brodzinski; Antonis Chatzinotas; Katharina Zeller; Delia Prywerek; Ingo Fetzer; Thomas Berg
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

4.  Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis.

Authors:  Cheuk-Chun Szeto; Ka-Bik Lai; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Chi-Bon Leung; Man-Ching Law; Vincent Yu; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 8.237

Review 5.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

6.  Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR (16S PCR) coupled with high-resolution melt analysis.

Authors:  Justin Hardick; Helen Won; Kevin Jeng; Yu-Hsiang Hsieh; Charlotte A Gaydos; Richard E Rothman; Samuel Yang
Journal:  J Clin Microbiol       Date:  2012-05-09       Impact factor: 5.948

7.  Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.

Authors:  Kevin J Fagan; Geraint B Rogers; Michelle Melino; Dionne M Arthur; Mary-Ellen Costello; Mark Morrison; Elizabeth E Powell; Katharine M Irvine
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

8.  Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension.

Authors:  Geraint B Rogers; Christopher J van der Gast; Kenneth D Bruce; Peter Marsh; Jane E Collins; Julian Sutton; Mark Wright
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

Review 9.  Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Authors:  Katharine Margaret Irvine; Isanka Ratnasekera; Elizabeth E Powell; David Arthur Hume
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

10.  Next- and Third-Generation Sequencing Outperforms Culture-Based Methods in the Diagnosis of Ascitic Fluid Bacterial Infections of ICU Patients.

Authors:  Hanna Goelz; Simon Wetzel; Negin Mehrbarzin; Stefan Utzolino; Georg Häcker; Mohamed Tarek Badr
Journal:  Cells       Date:  2021-11-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.